Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pingkui enema is a traditional Chinese medicine (TCM) prescription that has been used clinically for many years to treat diarrhea and dysentery. It is currently being investigated for its therapeutic potential in ulcerative colitis (UC). The mechanism of action involves the regulation of gut probiotics, specifically increasing the abundance of *Bifidobacterium*, and modulating inflammatory cytokines by reducing pro-inflammatory factors such as tumor necrosis factor alpha (TNF-α) and interleukin-8 (IL-8), while increasing anti-inflammatory interleukin-13 (IL-13). Additionally, Pingkui enema appears to protect the intestinal mucosal barrier, as indicated by reduced serum levels of D-lactic acid (D-LA) and diamine oxidase (DAO).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pingkui enema.